The Nobel Prize was awarded Monday for cancer immunology. The 2018 Nobel laureates James Allison and Tasuku Honjo found proteins known as immune checkpoints that can stop T-cells, causing them to pass over a cancer cell instead of attacking it. Checkpoint inhibitors drastically transformed the field of cancer immunology said Mario Sznol, co-director of the Cancer Immunology Program at YCC. He praised the decision to award Allison and Honjo, but said many others also deserved recognition. “One who didn’t get the Nobel Prize but made a major, major contribution to understanding this pathway and its role in the treatment of cancer is Dr. Lieping Chen, who’s here at Yale, and as far as I’m concerned, Dr. Chen also deserves part of the Nobel Prize.”
- October 04, 2018
Yale Cancer Center (YCC) scientist Lieping Chen, M.D., Ph.D., who pioneered cancer immunotherapy studies targeting the PD-1/PD-L1 pathway, is suggesting a dramatically different paradigm for research in the field.
- August 30, 2018
Smilow and the Yale Cancer Center's major Breakthroughs: From the first physician-in-chief of the Smilow Cancer Hospital to building translational bridges between clinical trials and basic science
- October 05, 2017
Lieping Chen, Ph.D., co-director of the Cancer Immunology Program at Yale Cancer Center and United Technologies Corporation Professor in Cancer Research and professor of immunobiology, of dermatology and of medicine at Yale School of Medicine, has been presented with the 2017 Warren Alpert Foundation Prize for transformative discoveries in the field of cancer immunology.
- June 07, 2017
Lieping Chen, Ph.D., the United Technologies Corporation Professor in Cancer Research and professor of immunobiology, of dermatology, and of medicine, is one of five scientists to receive the 2017 Warren Alpert Foundation Prize.
- February 27, 2017
Dr. Jacky Yeung, a fourth-year neurosurgery resident, has been awarded the AANS/CNS Section on Tumors Research Fellowship Grant from the Neurosurgery Research and Education Foundation (NREF) for a project entitled, “Immunogenetic profiling and targeting novel immune check point regulators in meningiomas.” Dr. Yeung will conduct his research under the mentorship of Dr. Lieping Chen, United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, and Dr. Murat Gunel, Nixdorff-German Professor and Chair of Department of Neurosurgery.
- September 16, 2016
Dr. Lieping Chen is a pioneer in the field of immuno-oncology and his discoveries have led to life-saving drugs for cancer patients. Now, with the support of the Yale Office of Cooperative Research, Dr. Chen has launched a startup—NextCure—that is poised to lead to even more breakthrough treatments.
- June 01, 2016
Medical Oncology and Hematology Graduating Fellows Honored - June 2016
- April 08, 2016
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear. Now, Yale researchers have identified a mechanism that offers this new insight into this protective effect. The findings were described in the April 8 journal of Science Advances.
- January 08, 2016
New Germantown biotech nets $67 million from investors, including Eli Lilly and Pfizer to fund research and development in Dr. Lieping Chen’s laboratory. Immuno-oncology has attracted growing notice over the past few years, but only a handful of drugs in the nascent field have been approved for broad public use. Two of those drugs leading the charge — Keytruda and Opdivo — target the PD-1/PD-L1 pathway that Chen is credited with innovating. Keytruda, manufactured by Merck, made headlines last year when former president Jimmy Carter said he was using it to treat cancerous tumors in his brain and liver. Carter said in December that he is cancer-free.